Reduced Myocardial Ischemia-Reperfusion Injury in Toll-Like Receptor 4-Deficient Mice

Circulation

Volumn 109, Issue 6, 2004, Pages 784-789

  Oyama, Jun Ichi ^a   Blais Jr , Charles ^a   Liu, Xiaoli ^b   Pu, Minying ^a   Kobzik, Lester ^d   Kelly, Ralph A ^e   Bourcier, Todd ^c  

^a Dept of Cardiovascular Medicine ^*

^b Pulmonary and Critical Care Division

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e GENZYME CORPORATION   (United States)

Author keywords

Inflammation; Ischemia; Myocardial infarction

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN; GAMMA INTERFERON; INTERLEUKIN 12; MYELOPEROXIDASE; THIOGLYCOLIC ACID; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; INFLAMMATION; MOUSE; NEUTROPHIL; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY;

ANIMALS; INFLAMMATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 1242336786     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000112575.66565.84     Document Type: Article

References (32)

1. Braunwald E. Personal reflections on efforts to reduce ischemic myocardial damage. Cardiovasc Res. 2002;56:332-338.
2. Ribichini F, Wijns W. Acute myocardial infarction: reperfusion treatment. Heart. 2002;88:298-305.
3. Maxwell SR, Lip GY. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int J Cardial. 1997;58:95-117.
4. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47.
5. Louis A, Cleland JG, Crabbe S, et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail. 2001;3:381-387.
6. Faxon DP, Gibbons RJ, Chronos NA, et al. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol. 2002;40:1199-1204.
7. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-680.
8. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085-2088.
9. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394-397.
10. Frantz S, Kobzik L, Kim YD, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104:271-280.
11. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001;104:3103-3108.
12. Baumgarten G, Knuefermann P, Nozaki N, et al. In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of toll-like receptor-4. J Infect Dis. 2001;183:1617-1624.
13. Nemoto S, Vallejo JG, Knuefermann P, et al. Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. Am J Pkysiol Heart Circ Physiol. 2002;282:H2316-H2323.
14. Zeuke S, Ulmer AJ, Kusumoto S, et al. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res. 2002;56:126-134.
15. Li M, Carpio DF, Zheng Y, et al. An essential role of the NF-κB/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol. 2001;166:7128-7135.
16. Ohashi K, Burkart V, Flohe S, et al. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol. 2000;164:558-561.
17. Yet SF, Tian R, Layne MD, et al. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res. 2001;89:168-173.
18. Poltorak A, Merlin T, Nielsen PJ, et al. A point mutation in the IL-12R beta 2 gene underlies the IL-12 unresponsiveness of Lps-defective C57BL/10ScCr mice. J Immunol. 2001;167:2106-2111.
19. Zhou RH, Shi Q, Gao HQ, et al. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J Atheroscler Thromb. 2001;8:30-32.
20. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18:655-673.
21. Sabroe I, Prince LR, Jones EC, et al. Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. J Immunol. 2003;170:5268-5275.
22. Segal BH, Kuhns DB, Ding L, et al. Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation. J Leukoc Biol. 2002;71:410-416.
23. Chenoweth DE. The properties of human C5a anaphylatoxin: the significance of C5a formation during hemodialysis. Contrib Nephrol. 1987;59:51-71.
24. Chandrasekar B, Smith JB, Freeman GL. Ischemia-reperfusion of rat myocardium activates nuclear factor-κB and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine. Circulation. 2001;103:2296-2302.
25. Baxter GF. The neutrophil as a mediator of myocardial ischemia-reperfusion injury: time to move on. Basic Res Cardiol. 2002;97:268-275.
26. Dhalla NS, Elmoselhi AB, Hata T, et al. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res. 2000;47:446-456.
27. Entman ML, Youker K, Shoji T, et al. Neutrophil induced oxidative injury of cardiac myocytes: a compartmented system requiring CD11b/CD18-ICAM-1 adherence. J Clin Invest. 1992;90:1335-1345.
28. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 1999;285:732-736.
29. Rhee SH, Hwang D. Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. J Biol Chem. 2000;275:34035-34040.
30. Vakeva AP, Agah A, Rollins SA, et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation. 1998;97:2259-2267.
31. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990;249:146-151.
32. Pinckard RN, Olson MS, Giclas PC, et al. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest. 1975;56:740-750.